kidney transplantation
Conditions
Interventions
p-ATG:On the day of surgery and the 1st, 2nd, 3rd, and 4th day after surgery, respectively
2 bottles of p-ATG each time
Basiliximab:On the day of surgery and the 4th day after surgery, respectively
1 bottle of Basiliximab each time
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Subjects with end-stage renal disease and suitable for first-time DCD kidney transplantation; 2) Male or female participants (Chinese residents) aged between 18 and 65 years (inclusive); 3) Kidney transplant recipients who plan to receive ABO blood type matching; 4) The peak of group reactive antibody (PRA) is less than 10% or the test result is negative; 5) Voluntary signing of informed consent form; 6) Immunosuppressive therapy based on calcineurin inhibitors (CNIs), mycophenolate mofetil (MMF), and prednisone.
Exclusion criteria
Exclusion criteria: (1) Individuals who are severely allergic to the test drug and unable to use it; (2) White blood cell count2 times the upper limit of normal (ULN); (11) Poor compliance or other situations that are not suitable for research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence, timing, and histological severity of AR within 6 months after transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocyte classification and function;The incidence and duration of delayed recovery of graft function;Changes in renal function;Patient and transplant kidney survival rate;The incidence of AE/ASE; | — |
Countries
China
Contacts
Public ContactXiaoming Ding
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed